echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Early predictor of disability in children due to serum AQP4 IgG positive neuromyelitis optica spectrum disease

    JNNP: Early predictor of disability in children due to serum AQP4 IgG positive neuromyelitis optica spectrum disease

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease of the central nervous system (CNS) that mainly affects the optic nerve and spinal cord
    .


    About 60%–80% of patients’ serum contains disease-specific aquaporin-4 antibody (AQP4 IgG), which leads to primary autoimmune astrocytosis with a characteristic recurrence process


    About 60%–80% of patients’ serum contains disease-specific aquaporin-4 antibody (AQP4 IgG), which leads to primary autoimmune astrocytosis with a characteristic recurrence process


    Only about 5% of AQP4 IgG seropositive NMODS are pediatric cases
    .


    To the rarity of the disease, long-term clinical outcome data AQP4 IgG positive serum pediatric patients rarely and require further evidence, particularly because new treatments are emerging, this is the result of a long-term study, the study is from a few A relatively large child-onset AQP4 IgG NMOSD cohort recruited by the British Neurology Center


    The subject of the study was a relatively large cohort of childhood-onset AQP4 IgG NMOSD recruited from several British neurology centers


    A retrospective analysis from six British optic neuromyelitis centers
    .


    All data are standard clinical care data of their respective centers (6 months neurological and ophthalmological follow-up, serum AQP4 IgG detection, diagnostic magnetic resonance imaging and cerebrospinal fluid-CSF)



    A total of 49 children with AQP4 IgG (38.
    8% were white, 34.
    7% were black, 20.
    4% were Asian, and 6.
    1% were mixed) were enrolled.
    The average age of onset of the patients was 12±4.
    1 years and 87.
    7% were women
    .


    26.


    A total of 49 children with AQP4 IgG (38.


    Of the 79-month median duration of disease in the cohort, 34.


    Early predictors of the probability of first relapse, visual disability, EDSS score, and cognitive impairment

    Early predictors of the probability of first relapse, visual disability, EDSS score and cognitive impairment

    Children under 12 years old relapse earlier than children 12-18 years old
    .


    Compared with people under the age of 12, blacks account for a larger proportion of people aged 12-18


    In summary, age of onset, race, symptoms of onset, and resistance to acute treatment at onset can predict first relapse and long-term disability
    .


    The understanding of these predictors may help promote future pediatric clinical trials and guide early treatment decisions for AQP4 IgG NMOSD
    .

    Age of onset, race, symptoms of onset, and resistance to acute treatment at onset can predict first relapse and long-term disability
    .
    Age of onset, race, symptoms of onset, and resistance to acute treatment at onset can predict first relapse and long-term disability
    .
    CameraV ,MessinaS ,ElhaddKT CameraV Camera MessinaS Messina ElhaddKT ElhaddKT Elhadd , et al Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders , et al Journal of Neurology, Neurosurgery & PsychiatryPublished Online First:28 September 2021.
    Published Online First: doi: 10.
    1136/jnnp-2021-327206doi:Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.